Zhicheng Zhang
Hangzhou, 310027, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
A Self-Assembling Peptide Platform for Intratumoral Doxorubicin Delivery and Preliminary Immune-Related Modulation in B16-F10 Melanoma.
Journal: Biomedicines
Published: June 21, 2026
Exosomal NEAT1 from tumor stem cells induces SIRPA+ macrophages to enhance immune evasion and glioblastoma progression via upregulating the HSP90B1/STAT3 axis.
Journal: Journal of experimental & clinical cancer research : CR
Published: December 01, 2025
The Modern Numerical and Experimental Methods for the Sound Absorbing Characteristics of Dissipative Sound Absorbing Materials: A Review.
Journal: Materials (Basel, Switzerland)
Published: October 16, 2025
Spatial Targeting of Sialic Acid Receptors for MRI/BNCT-Integrated Boron Drug-Based Antitumor Therapy.
Journal: Pharmaceutical research
Published: September 01, 2025
Manganese-enriched nanoboron agent amplifies BNCT efficacy via pyroptosis-mediated immune activation and STING pathway synergy.
Journal: Journal of nanobiotechnology
Published: August 28, 2025
TMEM165 promotes glioblastoma progression through epithelial-mesenchymal transition-mediated invasion and temozolomide chemoresistance.
Journal: International journal of biological macromolecules
Published: May 21, 2025
Amlodipine synergizes with temozolomide against glioma stem cells by modulating MGMT expression through downregulation of the AKT/GSK3β/β-catenin axis.
Journal: Cellular signalling
Published: May 12, 2025
Amlodipine exerts inhibitory effects against glioma stem cells through degrading EGFR and down-regulating its downstream pro-survival pathways.
Journal: Cell death discovery
Published: March 03, 2025
Polyethylene glycol complexed with boronophenylalanine as a potential alternative to fructose-boronophenylalanine complexation to increase cellular uptake for BNCT treatment.
Journal: Drug development and industrial pharmacy
Published: January 11, 2025
KIF4A Inhibits Ferroptosis in Glioblastoma via the CHMP4B/GPX4 Axis and Promotes Temozolomide Resistance.
Journal: Molecular carcinogenesis
Published: December 21, 2024
KIF4A Promotes Glioblastoma Malignant Progression and Transmission of Temozolomide Resistance in the Tumor Microenvironment via the HIF1A/VEGFA Axis.
Journal: CNS neuroscience & therapeutics
Published: December 18, 2024
Last Updated: 09/26/2026